Akari Therapeutics PLC (AKTX)

[xr_biotech_consult]

Should AKTX push nomacopan to market, the potential here would be incredible. There are no approved treatments that are indicated for HSCT-TMA patients. However, the market surrounding the condition is a massive one.
In fact, experts expect that the HSCT-TMA market will grow to be worth well over $37 billion annually by the year 2025. That’s a big deal, especially when you consider that Akari Therapeutics is currently trading with a sub-$50 million market cap.
With no competition on the playing field, this relatively small biotech company could have a blockbuster on its hands, should the treatment be approved. So, keep your eyes peeled as this opportunity could be huge.